- Conditions
- Screening Colonoscopy, Surveillance Colonoscopy
- Interventions
- Screening or Surveillance Conventionall colonoscopy
- Procedure
- Lead sponsor
- Magentiq Eye LTD
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 952 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • New York, New York • Cleveland, Ohio + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1801–1824
of 4,778
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition
- Interventions
- filgrastim, cyclosporine, methylprednisolone, prednisone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 10 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
- Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 8
- States / cities
- Burbank, California • Encinitas, California • Fresno, California + 5 more
- Conditions
- Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Dexamethasone, Filgrastim-sndz, Laboratory Biomarker Analysis, Pomalidomide
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hodgkin's Lymphoma, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Non-hodgkin's Lymphoma, Myelodysplastic Syndrome
- Interventions
- Behavioral techniques
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, ADT, Relugolix
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more
- Conditions
- Kidney Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Perioperative/Postoperative Complications, Urinary Complications
- Interventions
- cold ischemia procedure, warm ischemia procedure
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- Orange, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
- Conditions
- Leukemia, Multiple Myeloma, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year and older
- Enrollment
- 1,340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
- Interventions
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201
- Biological
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Sapanisertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- carfilzomib, Dexamethasone, Clarithromycin, Lenalidomide
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pain, Cancer
- Interventions
- OraVescent fentanyl (OVF)
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 26
- States / cities
- Cullman, Alabama • Anaheim, California • Corona, California + 20 more
- Conditions
- Multiple Myeloma, Amyloidosis
- Interventions
- Tacrolimus, Equine Anti-thymocyte globulin, Kidney transplant from a related donor, Bone marrow transplant from a related donor, Total body irradiation 400 centigray (200 cGy X 2)
- Drug · Procedure · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, B Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Peripheral T Cell Lymphoma
- Interventions
- BR101801 (Phase Ia), BR101801 (Phase Ib)
- Drug
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Healthy Lifestyle, Obese, Men
- Interventions
- Diet, Exercise, Standard care
- Other
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Multiple Myeloma
- Interventions
- filgrastim, cisplatin, cyclophosphamide, dexamethasone, etoposide, thalidomide
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 93
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
- Conditions
- Breast Cancer
- Interventions
- TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC
- Drug
- Lead sponsor
- Agendia
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 9
- States / cities
- Mobile, Alabama • Clearwater, Florida • Miami, Florida + 6 more
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Belantamab mafodotin
- Drug
- Lead sponsor
- Cristiana Costa Chase, DO
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Clayton, North Carolina • Henderson, North Carolina • Laurinburg, North Carolina + 2 more
- Conditions
- Melanoma, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Breast Cancer
- Interventions
- IDC-G305
- Biological
- Lead sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- DARATUMUMAB, DURVALUMAB
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 12
- States / cities
- Duarte, California • Southington, Connecticut • Fort Wayne, Indiana + 8 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Cessation of continuous matinenace therapy
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Basal Cell Carcinoma in Basal Cell Nevus Syndrome
- Interventions
- ASN-002
- Biological
- Lead sponsor
- Ascend Biopharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostate Cancer
- Interventions
- ZD4054 15 mg, Placebo, ZD4054 10 mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Los Angeles, California • Gainsville, Florida + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Lenalidomide
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 44
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more